SAHPRA in Crisis! Regulator is Failing its Mandate and Medical Cannabis Sector is Feeling the Pain

SAHPRA’s unilateral decision to halt approval of any further Section 21 medical cannabis applications has spiralled into a crisis. Patients are being denied access to medication and service providers face uncertainty while the regulator remains silent.
The Case for Sun-Grown Cannabis

Sun grown cannabis is on the rise in the US as soaring input costs hit ‘indoor’, while ‘outdoor’ may foster a richer, more complex chemical profile.